基本统计
| CIK | 1720725 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Oyster Point Pharma Inc
SEC Filings (Chronological Order)
本页提供了美国证券交易委员会（SEC）备案的完整、按时间顺序排列的列表，不包括我们在其他地方提供的所有权备案。
| February 14, 2023 |
SC 13G/A 1 pt7213ga.htm SCHEDULE 13G/A, AMENDMENT #2 240.13d-102 Schedule 13G - Information to be included in statements filed pursuant to 240.13d-1(b), (c), and (d) and amendments thereto filed pursuant to 240.13d-2. Securities and Exchange Commission, Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* (Name of Issuer) Oyster Point Pharma, Inc. (Title |
|
| February 14, 2023 |
OYST / Oyster Point Pharma Inc / RTW INVESTMENTS, LP - OYSTER POINT PHARMA, INC. Passive Investment SC 13G/A 1 p23-0497sc13ga.htm OYSTER POINT PHARMA, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* Oyster Point Pharma, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 69242L106 (CUSIP Number) December 31, 2022 (Date of event which requires filing of this stateme |
|
| February 14, 2023 |
OYST / Oyster Point Pharma Inc / Paradigm Biocapital Advisors LP - SC 13G/A Passive Investment SC 13G/A 1 tm236410d4sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Oyster Point Pharma, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 69242L106 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this statement) |
|
| January 13, 2023 |
OYST / Oyster Point Pharma Inc / Versant Venture Capital VI, L.P. - SC 13D/A Activist Investment SC 13D/A 1 d391729dsc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-l(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 6)* OYSTER POINT PHARMA, INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) |
|
| January 13, 2023 |
15-12G 1 d415725d1512g.htm 15-12G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-39112 Oyster Point Pharma, Inc. (Exact |
|
| January 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 3, 2023 Oyster Point Pharma, Inc. (Exact name of Registrant as Specified in Charter) Delaware 001-39112 81-1030955 (State or Other Jurisdiction of Incorporation) (Commission |
|
| January 9, 2023 |
SC 13D/A 1 nea14-oyster18678.htm NEW ENTERPRISE ASSOCIATES 14, L.P. - OYSTER POINT PHARMA, INC. 13D/A(#2E) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* Oyster Point Pharma, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 69242L106 (CUSIP Number) Louis S. Citron, |
|
| January 5, 2023 |
OYST / Oyster Point Pharma Inc / InvOpps IV US, L.P. - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* Oyster Point Pharma, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 69242L106 (CUSIP Number) Carmen Taton Invus Financial Advisors, LLC 126 East 56th Street, 20th Floor New York, NY 10022 Tel: (212) 616-2555 |
|
| January 3, 2023 |
As filed with the Securities and Exchange Commission on January 3, 2023 As filed with the Securities and Exchange Commission on January 3, 2023 Registration No. |
|
| January 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO (Amendment No. 2) Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 OYSTER POINT PHARMA, INC. (Name of Subject Company) IRIS PURCHASER INC. (Offeror) A Wholly Owned Subsidiary of VIATRIS INC. (Parent of Offeror) (Names of Filing Persons (identifying status as off |
|
| January 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 3, 2023 Oyster Point Pharma, Inc. (Exact name of Registrant as Specified in Charter) Delaware 001-39112 81-1030955 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| January 3, 2023 |
Second Amended and Restated Bylaws of Oyster Point Pharma, Inc., dated as of January 3, 2023. Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF OYSTER POINT PHARMA, INC., a Delaware corporation ARTICLE I Business Offices The corporation (the ?Corporation?) shall have such offices either within or outside the State of Delaware and within or outside the United States, as the Board of Directors of the Corporation (the ?Board of Directors?) may from time to time determine or as the business of the Co |
|
| January 3, 2023 |
As filed with the Securities and Exchange Commission on January 3, 2023 As filed with the Securities and Exchange Commission on January 3, 2023 Registration No. |
|
| January 3, 2023 |
Press Release issued by Viatris on January 3, 2023.” EX-99.(A)(5)(E) 2 d442488dex99a5e.htm EX-99.(A)(5)(E) Exhibit (a)(5)(E) Viatris Closes Acquisitions of Oyster Point Pharma and Famy Life Sciences, Establishing New Viatris Eye Care Division Division Combines Oyster Point Pharma’s Eye Care Expertise with Famy Life Science’s Phase III-ready Pipeline and Lays Foundation for Viatris to Become a Global Eye Care Leader Acquisitions Have the Potential to |
|
| January 3, 2023 |
As filed with the Securities and Exchange Commission on January 3, 2023 As filed with the Securities and Exchange Commission on January 3, 2023 Registration No. |
|
| January 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 3) Oyster Point Pharma, Inc. (Name of Subject Company) Oyster Point Pharma, Inc. (Name of Person Filing Statement) Common Stock, $0.001 par value per share (Title of Class of Securities) 69242L106 ( |
|
| January 3, 2023 |
Exhibit 3.1 SECOND AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF OYSTER POINT PHARMA, INC. Oyster Point Pharma, Inc. (the ?Corporation?), a corporation organized and existing under the General Corporation Law of the State of Delaware, hereby certifies as follows: 1. The name of the Corporation is Oyster Point Pharma, Inc., and the original Certificate of Incorporation of the Corporation was |
|
| January 3, 2023 |
As filed with the Securities and Exchange Commission on January 3, 2023 As filed with the Securities and Exchange Commission on January 3, 2023 Registration No. |
|
| January 3, 2023 |
As filed with the Securities and Exchange Commission on January 3, 2023 As filed with the Securities and Exchange Commission on January 3, 2023 Registration No. |
|
| December 23, 2022 |
SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 2) Oyster Point Pharma, Inc. (Name of Subject Company) Oyster Point Pharma, Inc. (Name of Person Filing Statement) Common Stock, $0.001 par value per share (Title of Class of Securities) 6 |
|
| December 22, 2022 |
Exhibit 99.2 To: Oyster Point Employees From: Barry Rosenfeld, General Counsel Subject: Please read: Regarding Viatris Tender Offer Dear Oyster Point Colleagues, Following up on the email that I sent you this morning regarding the Viatris offer, if you hold your shares through Shareworks (this includes ESPP shares), you will receive a new personalized Letter of Transmittal via Docusign that has be |
|
| December 22, 2022 |
Exhibit 99.1 To: Oyster Point Employees From: Barry Rosenfeld, General Counsel Subject: Please read: Regarding Viatris Tender Offer Dear Oyster Point Colleagues, As you are aware, in November, Oyster Point announced that it had entered into a definitive agreement under which Viatris Inc. would acquire Oyster Point Pharma, through a tender offer. The press release we issued can be found here. If yo |
|
| December 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 Oyster Point Pharma, Inc. (Name of Subject Company) Oyster Point Pharma, Inc. (Name of Person Filing Statement) Common Stock, $0.001 par value per share (Title of Class of Securities) 69242L106 (CUSIP Number of Cl |
|
| December 22, 2022 |
Exhibit 99.3 EMPLOYEE TENDER FAQs ? I received some documents in the mail regarding the Viatris tender offer. What are these documents? ? If you hold your shares through Shareworks, you should have received certain documents in the mail from Morgan Stanley with respect to your shares of Oyster Point common stock held through your Shareworks account. These documents are also available online in you |
|
| December 21, 2022 |
OYST / Oyster Point Pharma Inc / InvOpps IV US, L.P. - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Oyster Point Pharma, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 69242L106 (CUSIP Number) Carmen Taton Invus Financial Advisors, LLC 126 East 56th Street, 20th Floor New York, NY 10022 Tel: (212) |
|
| December 9, 2022 |
SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO (Amendment No. 1) Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 OYSTER POINT PHARMA, INC. (Name of Subject Company) IRIS PURCHASER INC. (Offeror) A Wholly Owned Subsidiary of VIATRIS INC. (Parent of Offeror) (Names of Filing Persons (identifying sta |
|
| December 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 1) Oyster Point Pharma, Inc. (Name of Subject Company) Oyster Point Pharma, Inc. (Name of Person Filing Statement) Common Stock, $0.001 par value per share (Title of Class of Securities) 69242L106 ( |
|
| December 1, 2022 |
Form of Summary Newspaper Advertisement, as published in The New York Times on December 1, 2022.* Exhibit (a)(1)(F) This announcement is neither an offer to purchase nor a solicitation of an offer to sell Shares (as defined below), and the provisions herein are subject in their entirety to the provisions of the Offer (as defined below). |
|
| December 1, 2022 |
Exhibit (d)(5) EXECUTION VERSION STRICTLY CONFIDENTIAL CLEAN TEAM CONFIDENTIALITY AGREEMENT This Clean Team Confidentiality Agreement (the ?Agreement?) is entered into as of October 21, 2022, by and between Viatris Inc. |
|
| December 1, 2022 |
Form of Letter of Transmittal (including Internal Revenue Service Form W-9).* Exhibit (a)(1)(B) Letter of Transmittal to Tender Shares of Common Stock of OYSTER POINT PHARMA, INC. |
|
| December 1, 2022 |
Form of Letter to Clients for use by Brokers, Dealers, Banks, Trust Companies and Other Nominees.* Exhibit (a)(1)(E) Offer to Purchase All Outstanding Shares of Common Stock of OYSTER POINT PHARMA, INC. |
|
| December 1, 2022 |
Exhibit (d)(4) CONFIDENTIALITY AGREEMENT This Confidentiality Agreement (this ?Agreement?) is executed and entered into on June 28, 2022 (the ?Effective Date?), by and between Viatris Inc. |
|
| December 1, 2022 |
Retention Letter between Oyster Point, Inc. and Dan Lochner, dated November 6, 2022. Exhibit (e)(R) November 6, 2022 Daniel Lochner c/o last address on file with the Company Re: Retention Agreement Dear Dan: As you know, Oyster Point Pharma, Inc. |
|
| December 1, 2022 |
Exhibit 107 Calculation of Filing Fee Table SCHEDULE TO (Rule 14d-100) OYSTER POINT PHARMA, INC. |
|
| December 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 OYSTER POINT PHARMA, INC. (Name of Subject Company) IRIS PURCHASER INC. (Offeror) A Wholly Owned Subsidiary of VIATRIS INC. (Parent of Offeror) COMMON STOCK, $0.01 PAR VALUE (Title of Class of Securities) 69242L10 |
|
| December 1, 2022 |
Exhibit (e)(C) CONFIDENTIAL TENDER AND SUPPORT AGREEMENT This TENDER AND SUPPORT AGREEMENT (this ?Agreement?), dated as of November 7, 2022, is by and among Viatris Inc. |
|
| December 1, 2022 |
Exhibit (d)(3) Execution Version CONFIDENTIAL TENDER AND SUPPORT AGREEMENT This TENDER AND SUPPORT AGREEMENT (this ?Agreement?), dated as of November 7, 2022, is by and among Viatris Inc. |
|
| December 1, 2022 |
Offer to Purchase dated December 1, 2022.* Exhibit (a)(1)(A) Offer to Purchase All Outstanding Shares of Common Stock of Oyster Point Pharma, Inc. |
|
| December 1, 2022 |
Exhibit (e)(Q) November 6, 2022 Dr. Jeffrey A. Nau c/o last address on file with the Company Re: Retention Agreement Dear Jeff: As you know, Oyster Point Pharma, Inc., a Delaware corporation (the ?Company?), Viatris Inc., a Delaware corporation (?Parent?), and Iris Purchaser Inc., a Delaware corporation and wholly owned subsidiary of Parent (?Purchaser?), propose to enter into an Agreement and Pla |
|
| December 1, 2022 |
Form of Letter to Brokers, Dealers, Banks, Trust Companies and Other Nominees.* Exhibit (a)(1)(D) Offer to Purchase All Outstanding Shares of Common Stock of OYSTER POINT PHARMA, INC. |
|
| December 1, 2022 |
Form of Notice of Guaranteed Delivery.* Exhibit (a)(1)(C) Notice of Guaranteed Delivery for Offer to Purchase All Outstanding Shares of Common Stock of OYSTER POINT PHARMA, INC. |
|
| December 1, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 OYSTER POINT PHARMA, INC. (Name of Subject Company) OYSTER POINT PHARMA, INC. (Name of Person Filing Statement) Common Stock, $0.001 par value per share (Title of Class of Securiti |
|
| November 21, 2022 |
EXHIBIT 3 TENDER AND SUPPORT AGREEMENT This TENDER AND SUPPORT AGREEMENT (this “Agreement”), dated as of November 7, 2022, is by and among Viatris Inc. |
|
| November 21, 2022 |
Schedule 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Oyster Point Pharma, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 69242L106 (CUSIP Number) Louis S. Citron, Esq. New Enterprise Associates 1954 Greenspring Drive, Suite 600, Timonium, MD 21093 (410) 842 |
|
| November 16, 2022 |
SC14D9C 1 d396331dsc14d9c.htm SC14D9C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 Oyster Point Pharma, Inc. (Name of Subject Company) Oyster Point Pharma, Inc. (Name of Person Filing Statement) Common Stock, $0.001 par value per share (Title of Class of Sec |
|
| November 16, 2022 |
Exhibit 99.2 TO: [Oyster Point Speaker bureau speakers] FROM: [Speakers TLL or Marketing] DATE: [Insert Date] Subject: IMPORTANT: Tyrvaya? (varenicline solution) Speaker Bureau Update Dear Dr. [Speaker last name]: On November 11th, Oyster Point issued a press release announcing that we have entered into an agreement to be acquired by Viatris Inc. Viatris intends to acquire Oyster Point Pharma as t |
|
| November 16, 2022 |
Exhibit 99.1 To: Oyster Point Sales Force and TLLs From: Mike Campbell Subject: Field Direction Memo: Customer Inquiries - Oyster Point and Viatris Merger Agreement FIELD DIRECTION MEMO As you are aware, Oyster Point recently issued a press release announcing that we have entered into an agreement to be acquired by Viatris Inc. We recognize that you may receive customer inquiries related to this a |
|
| November 14, 2022 |
SC TO-C 1 d419178dsctoc.htm SC TO-C UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 OYSTER POINT PHARMA, INC. (Name of Subject Company) IRIS PURCHASER INC. (Offeror) A Wholly Owned Subsidiary of VIATRIS INC. (Parent of Offeror) COMMON STOCK, PAR VALUE $0.01 PER |
|
| November 14, 2022 |
Exhibit 99.1 The following communications are being filed in connection with the proposed acquisition of Oyster Point Pharma, Inc. by a wholly owned subsidiary of Viatris Inc. (?Viatris?). Michael Goettler, Chief Executive Officer of Viatris, posted the following message on LinkedIn on November 11, 2022: We made some exciting announcements earlier this week! In addition to delivering our seventh c |
|
| November 10, 2022 |
Exhibit 99.1 Oyster Point Pharma Reports Third Quarter 2022 Financial Results and Recent Business Highlights ?TYRVAYA? (Varenicline Solution) Nasal Spray Achieved Net Product Revenue of $5.6 Million in Q3?22 ?Approximately 34,000 TYRVAYA Prescriptions Filled During the Quarter, with Prescriptions Written by Approximately 6,100 Unique Eye Care Professionals ?November 1, 2022 Marked the First Annive |
|
| November 10, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 10, 2022 Oyster Point Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36002 81-1030955 (State or other jurisdiction of incorporation) (Commiss |
|
| November 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39112 OYSTER POINT PHARMA, INC. |
|
| November 8, 2022 |
Exhibit 2.1 AGREEMENT AND PLAN OF MERGER by and among: OYSTER POINT PHARMA, INC. VIATRIS INC., and IRIS PURCHASER INC. Dated as of November 7, 2022 TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS 2 Section1.1 Definitions 2 ARTICLE 2 THE OFFER 15 Section2.1 The Offer. 15 Section2.2 Company Actions. 18 ARTICLE 3 MERGER TRANSACTION 19 Section3.1 Merger of Purchaser into the Company 19 Section3.2 Effect |
|
| November 8, 2022 |
Exhibit 99.1 The following is an excerpt from the script for the conference call that was held at 8:30 a.m. Eastern Time on November 7, 2022, by Viatris Inc. The following does not purport to be a complete statement or summary of the conference call. Viatris Q3?22 November 7, 2022 Corporate Speakers: ? William Szablewski; Senior Key Executive; Viatris Inc. ? Robert Coury; Chairman of the Board; Vi |
|
| November 8, 2022 |
SC TO-C 1 d410049dsctoc.htm SC TO-C UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 OYSTER POINT PHARMA, INC. (Name of Subject Company) IRIS PURCHASER INC. (Offeror) A Wholly Owned Subsidiary of VIATRIS INC. (Parent of Offeror) COMMON STOCK, PAR VALUE $0.01 PER |
|
| November 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2022 Oyster Point Pharma, Inc. (Exact name of Registrant as Specified in Charter) Delaware 001-39112 81-1030955 (State or Other Jurisdiction of Incorporation) (Commission |
|
| November 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 Oyster Point Pharma, Inc. (Name of Subject Company) Oyster Point Pharma, Inc. (Name of Person Filing Statement) Common Stock, $0.001 par value per share (Title of Class of Securities) 69242L106 (CUSIP Number of Cl |
|
| November 7, 2022 |
Strategic Update: Our Path to Return to Growth November 7, 2022 Exhibit 99.1 This presentation contains ?forward-looking statements?. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements may include, without limitation, 2022 financial guidance; our outlooks and expectations with respect to the end |
|
| November 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 Oyster Point Pharma, Inc. (Name of Subject Company) Oyster Point Pharma, Inc. (Name of Person Filing Statement) Common Stock, $0.001 par value per share (Title of Class of Securities) 69242L106 (CUSIP Number of Cl |
|
| November 7, 2022 |
EX-99.1 Exhibit 99.1 Oyster Point Pharma, a Leading Ophthalmology-Focused Biopharmaceutical Company, to be Acquired by Viatris • Tender Offer to Acquire All Outstanding Shares of Oyster Point Pharma for $11.00 per Share, Plus a Contingent Value Right of Up To $2.00 per Share PRINCETON, N.J., November 7, 2022 (GLOBE NEWSWIRE) — Oyster Point Pharma, Inc. (Nasdaq: OYST), (“Oyster Point Pharma”), toda |
|
| November 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2022 Oyster Point Pharma, Inc. (Exact name of Registrant as Specified in Charter) Delaware 001-39112 81-1030955 (State or Other Jurisdiction of Incorporation) (Commission |
|
| November 7, 2022 |
Exhibit 99.1 Email to Employees From: Jeff Nau Email Subject Line: Oyster Point and Viatris Merger Agreement Oyster Point team, This morning, Oyster Point issued a press release [https://www.globenewswire.com/news-release/2022/11/07/2549667/0/en/Oyster-Point-Pharma-a-Leading-Ophthalmology-Focused-Biopharmaceutical- Company-to-be-Acquired-by-Viatris.html] announcing that we have entered into an agr |
|
| November 7, 2022 |
SC TO-C UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 OYSTER POINT PHARMA, INC. (Name of Subject Company) IRIS PURCHASER INC. (Offeror) A Wholly Owned Subsidiary of VIATRIS INC. (Parent of Offeror) COMMON STOCK, PAR VALUE $0.01 PER SHARE (Title of Class of Se |
|
| November 7, 2022 |
Exhibit 99.2 Viatris Announces Two Acquisitions to Create What it Expects to be a Leading Ophthalmology Franchise; Plans to Provide Strategic Update on its February 2022 Investor Event ? Expects Biocon Biologics Transaction to Close Shortly ? Intends to Begin Executing on Stock Repurchase Program ? Enters Agreements to Acquire Oyster Point Pharma and Famy Life Sciences for Aggregate of $700-$750 M |
|
| November 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 Oyster Point Pharma, Inc. (Name of Subject Company) Oyster Point Pharma, Inc. (Name of Person Filing Statement) Common Stock, $0.001 par value per share (Title of Class of Securities) 69242L106 (CUSIP Number of Cl |
|
| August 11, 2022 |
Form of Executive Employee Retention Equity and Bonus Letter Exhibit 10.1 Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential VIA DocuSign [***] [***] Re: Discretionary Equity Award and Bonus Dear [ ]: As was discussed [***], we appreciate your valuable contributions to Oyster Point Pharma, Inc. (the ?Company?) and it is the |
|
| August 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39112 OYSTER POINT PHARMA, INC. |
|
| August 11, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 11, 2022 Oyster Point Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36002 81-1030955 (State or other jurisdiction of incorporation) (Commissio |
|
| August 11, 2022 |
Exhibit 99.1 Oyster Point Pharma Reports Second Quarter 2022 Financial Results and Recent Business Highlights ?TYRVAYA? (Varenicline Solution) Nasal Spray Achieved Net Product Revenue of $4.7 Million in Q2?22 ?Approximately 30,000 TYRVAYA Prescriptions Filled During the Quarter, with Prescriptions Written by Over 5,700 Unique Eye Care Professionals; Launch to Date, Approximately 7,700 Unique Eye C |
|
| July 18, 2022 |
OYST / Oyster Point Pharma Inc / Paradigm Biocapital Advisors LP - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Oyster Point Pharma, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 69242L106 (CUSIP Number) July 7, 2022 (Date of Event Which Requires Filing of this statement) Check the appropriate box to designate the rul |
|
| July 18, 2022 |
Exhibit 1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the Common Stock, $0. |
|
| July 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 6, 2022 Oyster Point Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39112 81-1030955 (State or other jurisdiction of incorporation) (Commission F |
|
| June 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 23, 2022 Oyster Point Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39112 81-1030955 (State or other jurisdiction of incorporation) (Commission |
|
| June 28, 2022 |
Plan to Continue to Drive TYRVAYA® Launch with Approximately 150-200 Field-Based Sales Resources Exhibit 99.1 Oyster Point Pharma Announces Operating Expense Streamlining Plan June 28, 2022 Plan to Continue to Drive TYRVAYA? Launch with Approximately 150-200 Field-Based Sales Resources Plan Expected to Deliver Expense Savings of Approximately $6-8 Million in the Second Half of 2022 and $40-48 Million in 2023 Company to Refocus Research and Development Efforts on OC-01 (varenicline solution) N |
|
| June 8, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 3, 2022 Oyster Point Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39112 81-1030955 (State or other jurisdiction of incorporation) (Commission F |
|
| May 17, 2022 |
DEFA14A 1 oysterpoint-2022defa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission O |
|
| May 5, 2022 |
[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL, AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. |
|
| May 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39112 OYSTER POINT PHARMA, INC. |
|
| May 5, 2022 |
Oyster Point Pharma Reports First Quarter 2022 Financial Results and Recent Business Highlights Exhibit 99.1 Oyster Point Pharma Reports First Quarter 2022 Financial Results and Recent Business Highlights ?TYRVAYA? Nasal Spray Net Product Revenue of $2.7 Million in Q1?22 ?Approximately 19,000 TYRVAYA Prescriptions Filled During the Quarter, with Prescriptions Written by Over 4,500 Unique Eye Care Professionals ?Expansion of Commercial Coverage for TYRVAYA, with Up to Approximately 95 Million |
|
| May 5, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 5, 2022 Oyster Point Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36002 81-1030955 (State or other jurisdiction of incorporation) (Commission Fi |
|
| April 22, 2022 |
DEF 14A 1 proxy22.htm DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e |
|
| March 18, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 14, 2022 Oyster Point Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39112 81-1030955 (State or other jurisdiction of incorporation) (Commission |
|
| March 18, 2022 |
OYSTER POINT PHARMA ANNOUNCES RETIREMENT OF WILLIAM J. LINK FROM BOARD OF DIRECTORS Exhibit 99.1 OYSTER POINT PHARMA ANNOUNCES RETIREMENT OF WILLIAM J. LINK FROM BOARD OF DIRECTORS PRINCETON, N.J., Mar. 17, 2022 ? Oyster Point Pharma, Inc. (Nasdaq: OYST), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases, today announced that William J. Link, Ph.D., is re |
|
| February 24, 2022 |
Form of Performance Stock Unit Grant Package (2019 Equity Incentive Plan) Exhibit 10.17 [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. OYSTER POINT PHARMA, INC. 2019 EQUITY INCENTIVE PLAN PERFORMANCE UNIT AGREEMENT NOTICE OF PERFORMANCE UNIT GRANT Unless otherwise defined herein, the terms defined in the |
|
| February 24, 2022 |
Exhibit 99.1 Oyster Point Pharma Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Business Highlights ?FDA Approved TYRVAYATM (varenicline solution) Nasal Spray for the Treatment of the Signs and Symptoms of Dry Eye Disease on October 15, 2021 ?TYRVAYA Nasal Spray Net Product Revenue of $1.2 Million in Q4?21, plus $5.4 Million Recognized from Ji Xing Pharmaceuticals (Ji Xing) |
|
| February 24, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 24, 2022 Oyster Point Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39112 81-1030955 (State or other jurisdiction of incorporation) (Commiss |
|
| February 24, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39112 OYSTER POINT PHARMA, INC. |
|
| February 14, 2022 |
OYST / Oyster Point Pharma Inc / RTW INVESTMENTS, LP - OYSTER POINT PHARMA, INC. Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Oyster Point Pharma, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 69242L106 (CUSIP Number) December 31, 2021 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule purs |
|
| February 14, 2022 |
240.13d-102 Schedule 13G - Information to be included in statements filed pursuant to 240.13d-1(b), (c), and (d) and amendments thereto filed pursuant to 240.13d-2. Securities and Exchange Commission, Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.1)* (Name of Issuer) Oyster Point Pharma, Inc. (Title of Class of Securities) Common Stock, Par Value $0.00 |
|
| February 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Oyster Point Pharma, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 69242L106 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which t |
|
| January 21, 2022 |
2019 Employee Stock Purchase Plan Exhibit 99.2 OYSTER POINT PHARMA, INC. 2019 EMPLOYEE STOCK PURCHASE PLAN 1.Purpose. The purpose of the Plan is to provide employees of the Company and its Designated Companies with an opportunity to purchase Common Stock through accumulated Contributions. The Company intends for the Plan to have two components: a component that is intended to qualify as an ?employee stock purchase plan? under Sect |
|
| January 21, 2022 |
As filed with the Securities and Exchange Commission on January 21, 2022 As filed with the Securities and Exchange Commission on January 21, 2022 Registration No. |
|
| January 13, 2022 |
OYST / Oyster Point Pharma Inc / Versant Venture Capital VI, L.P. - SC 13D/A Activist Investment SC 13D/A 1 d476648dsc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-l(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 5)* OYSTER POINT PHARMA, INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) |
|
| January 13, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 9, 2022 Oyster Point Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39112 81-1030955 (State or other jurisdiction of incorporation) (Commissio |
|
| November 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39112 OYSTER POINT PHARMA, INC. |
|
| November 4, 2021 |
Exhibit 10.2 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential. LICENSE AND COLLABORATION AGREEMENT This License and Collaboration Agreement (this ?Agreement?) is entered into as of August 5, 2021 (the ?Effective Date?) by and betwee |
|
| November 4, 2021 |
Exhibit 10.1 Execution Version CREDIT AGREEMENT AND GUARANTY dated as of August 5, 2021 by and among OYSTER POINT PHARMA, INC., as the Borrower, THE SUBSIDIARY GUARANTORS FROM TIME TO TIME PARTY HERETO, as the Subsidiary Guarantors, THE LENDERS FROM TIME TO TIME PARTY HERETO, as the Lenders, and ORBIMED ROYALTY & CREDIT OPPORTUNITIES III, LP as the Initial Lender and Agent U.S. $125,000,000 TABLE |
|
| November 4, 2021 |
Oyster Point Pharma Reports Third Quarter 2021 Financial Results and Recent Business Highlights Exhibit 99.1 Oyster Point Pharma Reports Third Quarter 2021 Financial Results and Recent Business Highlights ?FDA Approval of TYRVAYA ? (varenicline solution) Nasal Spray for the Treatment of the Signs and Symptoms of Dry Eye Disease on October 15, 2021 ?Field Force Onboarding Completed During Q3?21, U.S. Launch of TYRVAYA Nasal Spray Initiated on Nov. 1st. TYRVAYA is Now Available at U.S. Regiona |
|
| November 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 4, 2021 Oyster Point Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36002 81-1030955 (State or other jurisdiction of incorporation) (Commissi |
|
| October 28, 2021 |
Exhibit 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, and that all subsequent amendments to this statement on Schedule 13G may be filed on behalf of each of the undersigned without the necessi |
|
| October 28, 2021 |
OYST / Oyster Point Pharma Inc / Point72 Asset Management, L.P. - SCHEDULE 13G Passive Investment 240.13d-102 Schedule 13G - Information to be included in statements filed pursuant to 240.13d-1(b), (c), and (d) and amendments thereto filed pursuant to 240.13d-2. Securities and Exchange Commission, Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.)* (Name of Issuer) Oyster Point Pharma, Inc. (Title of Class of Securities) Common Stock, Par Value $0.001 |
|
| October 27, 2021 |
OYST / Oyster Point Pharma Inc / Versant Venture Capital VI, L.P. - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-l(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 4)* OYSTER POINT PHARMA, INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 69242L106 (CUSIP Number) Vers |
|
| October 19, 2021 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 19, 2021 Oyster Point Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39112 81-1030955 (State or other jurisdiction of incorporation) (Commissi |
|
| October 19, 2021 |
Exhibit 10.1 Execution Version WAIVER AND AMENDMENT This WAIVER AND AMENDMENT (this ?Agreement?) is made and entered into as of October 19, 2021, by and among OYSTER POINT PHARMA, INC., a Delaware corporation (the ?Borrower?), the lenders party hereto (the ?Majority Lenders?) and ORBIMED ROYALTY & CREDIT OPPORTUNITIES III, LP, as administrative agent for the Lenders (as defined below) (in such cap |
|
| October 18, 2021 |
Exhibit 10.1 Execution Version CREDIT AGREEMENT AND GUARANTY dated as of August 5, 2021 by and among OYSTER POINT PHARMA, INC., as the Borrower, THE SUBSIDIARY GUARANTORS FROM TIME TO TIME PARTY HERETO, as the Subsidiary Guarantors, THE LENDERS FROM TIME TO TIME PARTY HERETO, as the Lenders, and ORBIMED ROYALTY & CREDIT OPPORTUNITIES III, LP as the Initial Lender and Agent U.S. $125,000,000 TABLE |
|
| October 18, 2021 |
Exhibit 99.1 Oyster Point Pharma Announces FDA Approval of TYRVAYA? (varenicline solution) Nasal Spray for the Treatment of the Signs and Symptoms of Dry Eye Disease ?TYRVAYA is the first and only nasal spray approved for the treatment of the signs and symptoms of dry eye disease ?TYRVAYA is designed to activate the trigeminal parasympathetic pathway resulting in increased production of basal tear |
|
| October 18, 2021 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 18, 2021 Oyster Point Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39112 81-1030955 (State or other jurisdiction of incorporation) (Commissi |
|
| August 5, 2021 |
Exhibit 10.1 Oyster Point Pharma, Inc. 2021 Inducement Plan Adopted by the Board of Directors: July 30, 2021 1.General. (a)Eligible Award Recipients. The only persons eligible to receive grants of Awards under this Plan are individuals who satisfy the standards for inducement grants under Nasdaq Marketplace Rule 5635(c)(4) or 5635(c)(3), if applicable, and the related guidance under Nasdaq IM 5635 |
|
| August 5, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39112 OYSTER POINT PHARMA, INC. |
|
| August 5, 2021 |
Form of Stock Option Grant Notice and Option Agreement for the 2021 Inducement Plan Exhibit 10.2 Oyster Point Pharma, Inc. Stock Option Grant Notice (2021 Inducement Plan) Oyster Point Pharma, Inc. (the ?Company?), pursuant to its 2021 Inducement Plan (the ?Plan?), has granted to you (?Optionholder?) an option to purchase the number of shares of the Common Stock set forth below (the ?Option?). Your Option is subject to all of the terms and conditions as set forth herein, and in t |
|
| August 5, 2021 |
As filed with the Securities and Exchange Commission on August 5, 2021 As filed with the Securities and Exchange Commission on August 5, 2021 Registration No. |
|
| August 5, 2021 |
Form of Restricted Stock Unit Grant Notice and Exhibit 10.3 Oyster Point Pharma, Inc. RSU Award Grant Notice (2021 Inducement Plan) Oyster Point Pharma, Inc. (the ?Company?) has awarded to you (the ?Participant?) the number of restricted stock units specified and on the terms set forth below in consideration of your services (the ?RSU Award?). Your RSU Award is subject to all of the terms and conditions as set forth herein and in the Company?s |
|
| August 5, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 5, 2021 Oyster Point Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36002 81-1030955 (State or other jurisdiction of incorporation) (Commission |
|
| August 5, 2021 |
Oyster Point Pharma Reports Second Quarter 2021 Financial Results and Recent Business Highlights EX-99 2 oystearningspressrelease-q.htm EX-99 Exhibit 99.1 Oyster Point Pharma Reports Second Quarter 2021 Financial Results and Recent Business Highlights •PDUFA Target Action Date for OC-01 (varenicline) Nasal Spray is October 17, 2021 •Initiated Hiring of U.S. Sales Representatives in July, with a Planned U.S. Launch of OC-01 (varenicline) Nasal Spray in Q4’21, if Approved by the FDA •Exclusive |
|
| August 2, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 30, 2021 Oyster Point Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39112 81-1030955 (State or other jurisdiction of incorporation) (Commission |
|
| August 2, 2021 |
Exhibit 99.1 Oyster Point Pharma Announces New Chairperson Appointment to Board of Directors Donald Santel joins as Chairman of the Board of Directors PRINCETON, N.J., August 2, 2021 (GLOBE NEWSWIRE) - Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat o |
|
| July 1, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 1, 2021 Oyster Point Pharma, Inc. (Exact name of Registrant as Specified in Charter) Delaware 001-39112 81-1030955 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| July 1, 2021 |
Varenicline Activity on SARS-CoV-2 Infection July 1, 2021 Exhibit 99.1 Disclaimers and Forward-looking Statements This presentation contains ?forward-looking statements? within the meaning of the Private Securities Litigation Reform Act of 1995 that reflect the current beliefs, expectations and assumptions of the ?Company regarding the future of the Company?s business, our future plans and strateg |
|
| July 1, 2021 |
Exhibit 99.2 Oyster Point Pharma Announces Preclinical Data Highlighting Potent Activity of OC-01 (varenicline) and OC-02 (simpinicline) Against of SARS-CoV-2 Virus and Variants ? Administration of OC-01 (varenicline) nasal spray to non-human primates was observed to inhibit viral replication in the nose within 24 hours of infectious SARS-CoV-2 challenge with absence of subgenomic RNA at Day 3 and |
|
| June 10, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 4, 2021 Oyster Point Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39112 81-1030955 (State or other jurisdiction of incorporation) (Commission F |
|
| June 3, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 3, 2021 Oyster Point Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39112 81-1030955 (State or other jurisdiction of incorporation) (Commission F |
|
| June 3, 2021 |
Exhibit 99.1 Oyster Point Pharma Announces Preclinical Study Results and Pipeline Expansion with Enriched Tear Film (ETF?) Gene Therapy to Target Ocular Surface Diseases ?Introduction of proprietary ETF? Gene Therapy and first gene candidate, nerve growth factor (NGF), to target Stages 2 and 3 Neurotrophic Keratopathy (NK) ?Preclinical study results from a 42-day proof-of-concept in vivo study dem |
|
| May 24, 2021 |
SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-l(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 3)* OYSTER POINT PHARMA, INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 69242L106 (CUSIP Number) Vers |
|
| May 6, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39112 OYSTER POINT PHARMA, INC. |
|
| May 6, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 6, 2021 Oyster Point Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36002 81-1030955 (State or other jurisdiction of incorporation) (Commission Fi |
|
| May 6, 2021 |
Oyster Point Pharma Reports First Quarter 2021 Financial Results and Recent Business Highlights Exhibit 99.1 Oyster Point Pharma Reports First Quarter 2021 Financial Results and Recent Business Highlights ?PDUFA Target Action Date for OC-01 (varenicline) Nasal Spray is October 17, 2021 ?Planned U.S. Launch of OC-01 (varenicline) Nasal Spray in Q4 2021, if approved by the FDA ?OLYMPIA Phase 2 Study on Track, with Planned Enrollment of the First Patient in 1H 2021 ?Continued Organizational Adv |
|
| April 23, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defi |
|
| April 23, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| April 5, 2021 |
Exhibit 99.1 Oyster Point Pharma Announces New Appointment to Board of Directors George Eliades joins the Board of Directors PRINCETON, N.J., April 5, 2021 (GLOBE NEWSWIRE) ? Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases, tod |
|
| April 5, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 2, 2021 Oyster Point Pharma, Inc. (Exact name of Registrant as Specified in its Charter) Delaware 001-39112 81-1030955 (State or other Jurisdiction of Incorporation) (Commission |
|
| April 5, 2021 |
SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-l(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 2)* OYSTER POINT PHARMA, INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 69242L106 (CUSIP Number) Vers |
|
| March 31, 2021 |
As filed with the Securities and Exchange Commission on March 31, 2021 Registration No. |
|
| March 2, 2021 |
Exhibit 99.1 Oyster Point Pharma Announces FDA Acceptance for Filing New Drug Application for OC-01 (varenicline) Nasal Spray for the Treatment of Signs and Symptoms of Dry Eye Disease ? Prescription Drug User Fee Act (PDUFA) target action date is October 17, 2021 ? U.S. Food and Drug Administration (FDA) has stated that it does not intend to hold an advisory committee meeting to discuss this appl |
|
| March 2, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 2, 2021 Oyster Point Pharma, Inc. (Exact name of Registrant as Specified in Charter) Delaware 001-39112 81-1030955 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| March 1, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-l(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 1)* OYSTER POINT PHARMA, INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 69242L106 (CUSIP Number) Versant Ventu |
|
| February 18, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 18, 2021 Oyster Point Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39112 81-1030955 (State or other jurisdiction of incorporation) (Commiss |
|
| February 18, 2021 |
Exhibit 99.1 Oyster Point Pharma Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Business Highlights •OC-01 (Varenicline) Nasal Spray New Drug Application (NDA) Submitted to the U.S. Food and Drug Administration (FDA) for the Treatment of Signs and Symptoms of Dry Eye Disease on December 17, 2020 •Phase 2 Clinical Trial Protocol of OC-01 (Varenicline) Nasal Spray in Patients |
|
| February 18, 2021 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39112 OYSTER POINT PHARMA, INC. |
|
| February 18, 2021 |
Outside Director Compensation Policy. Exhibit 10.9 OYSTER POINT PHARMA, INC. OUTSIDE DIRECTOR COMPENSATION POLICY (Adopted on January 21, 2021, effective as of the 2021 Annual Meeting) Oyster Point Pharma, Inc. (the ?Company?) believes that the granting of equity and cash compensation to its members of the Board of Directors (the ?Board,? and members of the Board, ?Directors?) represents a powerful tool to attract, retain and reward D |
|
| February 12, 2021 |
Joint Filing Statement Pursuant to Rule 13d-1(k)(1) Exhibit 1 Joint Filing Statement Pursuant to Rule 13d-1(k)(1) The undersigned hereby consent and agree to the joint filing of Schedule 13G Amendment No. |
|
| February 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Oyster Point Pharma, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 69242L106 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which thi |
|
| December 18, 2020 |
Up to $100,000,000 Common Stock 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-249881 PROSPECTUS SUPPLEMENT (To prospectus dated November 16, 2020) Up to $100,000,000 Common Stock We have entered into a sales agreement with Cowen and Company, LLC, or Cowen, relating to shares of our common stock offered by this prospectus supplement and the accompanying prospectus. In accordance with the terms of t |
|
| December 18, 2020 |
Financial Statements and Exhibits, Other Events - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 18, 2020 Oyster Point Pharma, Inc. (Exact name of Registrant as Specified in Charter) Delaware 001-39112 81-1030955 (State or Other Jurisdiction of Incorporation) (Commission |
|
| December 18, 2020 |
EX-99.1 Exhibit 99.1 Oyster Point Pharma Submits New Drug Application to the U.S. Food and Drug Administration for OC-01 (varenicline) Nasal Spray for the Treatment of Signs and Symptoms of Dry Eye Disease The NDA submission is based on efficacy and safety results from a comprehensive clinical trial program conducted in patients with a broad range of dry eye disease. PRINCETON, N.J. – Dec. 18, 202 |
|
| December 2, 2020 |
EX-99.1 Exhibit 99.1 Oyster Point Pharma Submits a Phase 2 Clinical Trial Protocol to Evaluate OC-01 Nasal Spray for Neurotrophic Keratitis (NK) Planned enrollment of the first patient in the OLYMPIA Phase 2 study in 1H 2021 PRINCETON, N.J. – Dec. 1, 2020 (GLOBE NEWSWIRE) – Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development an |
|
| December 2, 2020 |
Financial Statements and Exhibits, Other Events - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 1, 2020 Oyster Point Pharma, Inc. (Exact name of Registrant as Specified in Charter) Delaware 001-39112 81-1030955 (State or Other Jurisdiction of Incorporation) (Commission |
|
| November 12, 2020 |
CORRESP OYSTER POINT PHARMA, INC. 202 Carnegie Center, Suite 109 Princeton, New Jersey 08540 (609) 382-9032 November 12, 2020 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Re: Oyster Point Pharma, Inc. Registration Statement on Form S-3 Filed November 5, 2020 File No. 333-249881 Ladies an |
|
| November 5, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 5, 2020 Oyster Point Pharma, Inc. (Exact name of Registrant as Specified in its Charter) Delaware 001-39112 81-1030955 (State or other Jurisdiction of Incorporation) (Commiss |
|
| November 5, 2020 |
S-3 Table of Contents As filed with the Securities and Exchange Commission on November 5, 2020 Registration No. |
|
| November 5, 2020 |
Form of Indenture between the Registrant and one or more trustees to be named. EX-4.5 Exhibit 4.5 OYSTER POINT PHARMA, INC. Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of Debt Securities TABLE OF CONTENTS PAGE ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01 Designation and Terms of Securities 5 Section 2.02 Form of Securities and Trustee’s Certificate 8 Sec |
|
| November 5, 2020 |
Form of Debt Securities Warrant Agreement and Warrant Certificate. EX-4.9 Exhibit 4.9 OYSTER POINT PHARMA, INC. AND , AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OF OYSTER POINT PHARMA, INC. FORM OF DEBT SECURITIES WARRANT AGREEMENT THIS DEBT SECURITIES WARRANT AGREEMENT (this “Agreement”), dated as of [●], between OYSTER POINT PHARMA, INC., a Delaware corporation (the “Company”), and [●], a [corporation] [national banking association] org |
|
| November 5, 2020 |
Form of Common Stock Warrant Agreement and Warrant Certificate. EX-4.7 Exhibit 4.7 OYSTER POINT PHARMA, INC. AND , AS WARRANT AGENT FORM OF COMMON STOCK WARRANT AGREEMENT DATED AS OF OYSTER POINT PHARMA, INC.FORM OF COMMON STOCK WARRANT AGREEMENT THIS COMMON STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [•], between OYSTER POINT PHARMA, INC., a Delaware corporation (the “Company”), and [•], a [corporation][national banking association] organized and |
|
| November 5, 2020 |
Form of Preferred Stock Warrant Agreement and Warrant Certificate. EX-4.8 Exhibit 4.8 OYSTER POINT PHARMA, INC. AND , AS WARRANT AGENT FORM OF PREFERRED STOCK WARRANT AGREEMENT DATED AS OF OYSTER POINT PHARMA, INC. FORM OF PREFERRED STOCK WARRANT AGREEMENT THIS PREFERRED STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [•], between OYSTER POINT PHARA, INC., a Delaware corporation (the “Company”), and [•], a [corporation] [national banking association] orga |
|
| November 5, 2020 |
Sales Agreement, dated November 5, 2020, by and between the Company and Cowen and Company, LLC. EX-1.2 Exhibit 1.2 OYSTER POINT PHARMA, INC. $100,000,000 COMMON STOCK SALES AGREEMENT November 5, 2020 Cowen and Company, LLC 599 Lexington Avenue New York, NY 10022 Ladies and Gentlemen: Oyster Point Pharma, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“Cowen”), as follows: 1. Issuance and Sale of Shares. The Company agrees |
|
| November 5, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 5, 2020 Oyster Point Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36002 81-1030955 (State or other jurisdiction of incorporation) (Commissi |
|
| November 5, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39112 OYSTER POINT PHARMA, INC. |
|
| November 5, 2020 |
EX-99.1 NASDAQ: OYST Focused on Transformative Therapies for the Ocular Surface Corporate Presentation November 2020 Exhibit 99.1 Disclaimers and Forward-looking Statements This presentation contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 that reflect the current beliefs, expectations and assumptions of Oyster Point Pharma, Inc. (the |
|
| November 5, 2020 |
Oyster Point Pharma Reports Third Quarter 2020 Financial Results and Recent Business Highlights Exhibit 99.1 Oyster Point Pharma Reports Third Quarter 2020 Financial Results and Recent Business Highlights •OC-01 New Drug Application (NDA) Submission to U.S. Food and Drug Administration (FDA) for Signs and Symptoms of Dry Eye Disease Remains on Track for Q4 2020 •OC-01 Investigational New Drug (IND) Application Submission to FDA for Neurotrophic Keratitis (NK) Remains on Track for Q4 2020 •Ca |
|
| October 9, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 8, 2020 Oyster Point Pharma, Inc. (Exact name of Registrant as Specified in its Charter) Delaware 001-39112 81-1030955 (State or other Jurisdiction of Incorporation) (Commissi |
|
| October 9, 2020 |
EX-99.1 Exhibit 99.1 Oyster Point Pharma Announces Board of Directors Leadership Changes and New Appointment as the Company Advances into Next Phase of Growth Ali Behbahani, M.D. takes on role of Chairperson of the Board Michael G. Atieh joins the Board of Directors as Chairperson of the Audit Committee PRINCETON, N.J., Oct. 8, 2020 — Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biop |
|
| August 5, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39112 OYSTER POINT PHARMA, INC. |
|
| August 5, 2020 |
Oyster Point Pharma Reports Second Quarter 2020 Financial Results and Recent Business Highlights Exhibit 99.1 Oyster Point Pharma Reports Second Quarter 2020 Financial Results and Recent Business Highlights •OC-01 New Drug Application (NDA) Submission to U.S. Food and Drug Administration (FDA) for Signs and Symptoms of Dry Eye Disease (DED) Planned for Q4 2020 •Cash and Cash Equivalents of $226.7 million as of June 30, 2020 •Conference Call and Webcast Scheduled for 8:30 am ET today PRINCETON |
|
| August 5, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 5, 2020 Oyster Point Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39112 81-1030955 (State or other jurisdiction of incorporation) (Commission |
|
| June 9, 2020 |
oysterpointinvestorprese Corporate Presentation June 2020 NASDAQ: OYST Disclaimers and Forward-looking Statements This presentation contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 that reflect the current beliefs, expectations and assumptions of Oyster Point Pharma, Inc. |
|
| June 9, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 8, 2020 Oyster Point Pharma, Inc. (Exact name of Registrant as Specified in Charter) Delaware 001-39112 81-1030955 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| June 5, 2020 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 5, 2020 Oyster Point Pharma, Inc. (Exact name of Registrant as Specified in Charter) Delaware 001-39112 81-1030955 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| May 22, 2020 |
Joint Filing Statement Pursuant to Rule 13d-1(k)(1) Exhibit 1 Joint Filing Statement Pursuant to Rule 13d-1(k)(1) The undersigned hereby consent and agree to the joint filing of Schedule 13G under the Securities Exchange Act of 1934, as amended, with respect to the Common Stock of Oyster Point Pharma, Inc. |
|
| May 22, 2020 |
OYST / Oyster Point Pharma, Inc. / RTW INVESTMENTS, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| May 18, 2020 |
424B4 Table of Contents Filed Pursuant to Rule 424(b)(4) Registration No. 333-238194 3,750,000 Shares COMMON STOCK We are offering 3,750,000 shares of our common stock. Our common stock is listed on the Nasdaq Global Select Market under the symbol “OYST.” On May 14, 2020, the last reported sale price of our common stock on the Nasdaq Global Select Market was $32.03 per share. We are an “emerging g |
|
| May 15, 2020 |
Oyster Point Pharma Announces Pricing of an Upsized Offering of Common Stock EX-99.1 Exhibit 99.1 Oyster Point Pharma Announces Pricing of an Upsized Offering of Common Stock PRINCETON, N.J., May 15, 2020 (GLOBE NEWSWIRE) — Oyster Point Pharma, Inc., a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases, today announced the pricing of its underwritte |
|
| May 15, 2020 |
Financial Statements and Exhibits, Other Events 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2020 Oyster Point Pharma, Inc. (Exact name of Registrant as Specified in Charter) Delaware 001-39112 81-1030955 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 15, 2020 |
POS EX As filed with the U.S. Securities and Exchange Commission on May 14, 2020 Registration No. 333-238194 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT Under The Securities Act of 1933 OYSTER POINT PHARMA, INC. (Exact name of Registrant as specified in its charter) Delaware 2836 81-1030955 (State or othe |
|
| May 14, 2020 |
S-1/A Table of Contents As filed with the Securities and Exchange Commission on May 14, 2020. |
|
| May 14, 2020 |
S-1MEF As filed with the U.S. Securities and Exchange Commission on May 14, 2020 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT Under The Securities Act of 1933 OYSTER POINT PHARMA, INC. (Exact name of Registrant as specified in its charter) Delaware 2836 81-1030955 (State or other jurisdiction of incorporation or organ |
|
| May 13, 2020 |
FWP Filed pursuant to Rule 433 of the Securities Act of 1933 Issuer Free Writing Prospectus dated May 13, 2020 Relating to the Preliminary Prospectus dated May 12, 2020 Registration Statement File No. |
|
| May 12, 2020 |
CORRESP J.P. Morgan Securities LLC 383 Madison Avenue New York, New York 10179 Cowen and Company, LLC 599 Lexington Avenue New York, New York 10022 Piper Sandler & Co. 345 Park Avenue, Suite 1200 New York, NY 10154 May 12, 2020 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Oyster Point Pharma, Inc. Registration Statement |
|
| May 12, 2020 |
S-1 Table of Contents As filed with the Securities and Exchange Commission on May 12, 2020. |
|
| May 12, 2020 |
CORRESP 202 Carnegie Center, Suite 109 Princeton, New Jersey 08540 VIA EDGAR May 12, 2020 U. |
|
| May 12, 2020 |
Form of Underwriting Agreement, including Form of Lock-up Agreement EX-1.1 Exhibit 1.1 OYSTER POINT PHARMA, INC. [●] Shares of Common Stock Underwriting Agreement [●], 2020 J.P. Morgan Securities LLC Cowen and Company, LLC Piper Sandler & Co. As Representatives of the several Underwriters listed in Schedule 1 hereto c/o J.P. Morgan Securities LLC 383 Madison Avenue New York, New York 10179 c/o Cowen and Company, LLC 599 Lexington Avenue New York, New York 10022 c/ |
|
| May 11, 2020 |
Oyster Point Pharma Reports First Quarter 2020 Financial Results and Recent Business Highlights Announces Positive Results in ONSET-2 Phase 3 Trial of OC-01 Nasal Spray for the Treatment of the Signs and Symptoms of Dry Eye Disease ONSET-2 Data Enables NDA Submission in 2H 2020 Cash and Cash Equivalents of $128. |
|
| May 11, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39112 OYSTER POINT PHARMA, INC. |
|
| May 11, 2020 |
OYSTER POINT PHARMA ANNOUNCES POSITIVE RESULTS IN ONSET-2 PHASE 3 TRIAL OF OC-01 NASAL SPRAY FOR THE TREATMENT OF THE SIGNS AND SYMPTOMS OF DRY EYE DISEASE ONSET-2 met the prespecified primary endpoint in both doses tested, demonstrating statistically significant improvement in Schirmer’s score from baseline to Week 4 in subjects receiving OC-01 nasal spray versus control (p<0. |
|
| May 11, 2020 |
oystonset2toplinedatafin ONSET-2 Phase 3 Study Top-line Results May 11, 2020 NASDAQ: OYST Disclaimers and Forward-Looking Statements This presentation contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 that reflect the current beliefs, expectations and assumptions of Oyster Point Pharma, Inc. |
|
| May 11, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 11, 2020 Oyster Point Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39112 81-1030955 (State or other jurisdiction of incorporation) (Commission F |
|
| May 11, 2020 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2020 Oyster Point Pharma, Inc. (Exact name of Registrant as Specified in Charter) Delaware 001-39112 81-1030955 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| April 27, 2020 |
DRS Table of Contents Confidential Treatment Requested by Oyster Point Pharma, Inc. |
|
| April 22, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant Filed by a party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) Definitive Proxy State |
|
| April 22, 2020 |
OYST / Oyster Point Pharma, Inc. DEF 14A - - DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant Filed by a party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) Definitive Proxy State |
|
| March 30, 2020 |
Exhibit 99.2 ITEM 1A. RISK FACTORS Investing in our common stock involves a high degree of risk. Careful consideration should be given to the following risk factors, in addition to the other information set forth in this Annual Report on Form 10-K and in other documents that we have filed and will file with the SEC, in evaluating our company and our business. Additional risks and uncertainties not |
|
| March 30, 2020 |
Exhibit 99.1 Oyster Point Pharma Completes Enrollment in ONSET-2 Pivotal Phase 3 Clinical Trial of OC-01 Nasal Spray for Dry Eye Disease and Provides COVID-19 Business Update ONSET-2 Phase 3 Top-Line Data Expected by End of Q2 2020 NDA Submission Expected During 2H 2020 PRINCETON, N.J., March 30, 2020 [BUSINESS WIRE] - Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical co |
|
| March 30, 2020 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 30, 2020 Oyster Point Pharma, Inc. (Exact name of Registrant as Specified in Charter) Delaware 001-39112 81-1030955 (State or Other Jurisdictionof Incorporation) (CommissionFile |
|
| February 27, 2020 |
Oyster Point Pharma Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Business Highlights ONSET-2 Phase 3 Top-Line Data Expected by End of Q2 2020 Cash and Cash Equivalents of $139. |
|
| February 27, 2020 |
OYST / Oyster Point Pharma, Inc. 10-K - Annual Report - 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39112 OYSTER POINT PHARMA, INC. |
|
| February 27, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 27, 2020 Oyster Point Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39112 81-1030955 (State or other jurisdiction of incorporation) (Commiss |
|
| February 27, 2020 |
Exhibit 4.1 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following summary describes our common stock and preferred stock, as well as certain provisions of our amended and restated certificate of incorporation and amended and restated bylaws. This summary does not purport to be complete and is qualified in its entirety by t |
|
| January 14, 2020 |
EX-99.1 Exhibit 99.1 January 2020 Corporate Update NASDAQ: OYSTExhibit 99.1 January 2020 Corporate Update NASDAQ: OYST Disclaimers and Forward Looking Statements This presentation contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 that reflect the current beliefs, expectations and assumptions of Oyster Point Pharma, Inc. (the “Company,” |
|
| January 14, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 14, 2020 Oyster Point Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39112 81-1030955 (State or other jurisdiction of incorporation) (Comm |
|
| January 13, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 12, 2020 Oyster Point Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39112 81-1030955 (State or other jurisdiction of incorporation) (Comm |
|
| January 13, 2020 |
EX-99.1 Exhibit 99.1 OYSTER POINT PHARMA’S OC-01 NASAL SPRAY MEETS PRIMARY ENDPOINT IN PHASE 2 MYSTIC TRIAL IN SUBJECTS WITH DRY EYE DISEASE • OC-01 nasal spray showed a statistically significant improvement in Schirmer’s score at Day 84 in both doses tested compared to control • OC-01 nasal spray is a preservative-free, aqueous, nicotinic agonist nasal spray designed to activate the trigeminal pa |
|
| January 13, 2020 |
EX-99.2 NASDAQ: OYST January 13, 2020 PHASE II TOPLINE DATA RELEASE MYSTIC The Study In Dry Eye Disease Exhibit 99.2 Disclaimers and Forward Looking Statements This presentation contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 that reflect the current beliefs, expectations and assumptions of Oyster Point Pharma, Inc. (the “Company,” “ |
|
| December 3, 2019 |
Oyster Point Pharma Reports Third Quarter 2019 Financial Results and Recent Business Highlights ZEN Phase 1 top-line data Closed IPO financing and received $92. |
|
| December 3, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 3, 2019 Oyster Point Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39112 81-1030955 (State or other jurisdiction of incorporation) (Commissi |
|
| December 3, 2019 |
OYST / Oyster Point Pharma, Inc. 10-Q - Quarterly Report - 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39112 OYSTER POINT PHARMA, INC. |
|
| November 14, 2019 |
EX-99.1 Exhibit 1 JOINT FILING AGREEMENT The undersigned agree that the statement on Schedule 13D with respect to the common stock, $0.0001 par value per share, of Oyster Point Pharma, Inc., a Delaware corporation, dated as of November 14, 2019, is, and any amendments thereto signed by each of the undersigned shall be, filed on behalf of each of them pursuant to and in accordance with the provisio |
|
| November 14, 2019 |
OYST / Oyster Point Pharma, Inc. / Versant Venture Capital Vi, L.p. - SC 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-l(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. )* OYSTER POINT PHARMA, INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 69242L106 (CUSIP Number) Versant Ventur |
|
| November 14, 2019 |
OYST / Oyster Point Pharma, Inc. / Invopps Gp Iv, L.l.c. - SC 13D Activist Investment SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Oyster Point Pharma, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 69242L106 (CUSIP Number) InvOpps GP IV, L.L.C. 126 East 56th Street, 20th Floor New York, NY 10022 Tel: (212) 616-2555 with a copy to |
|
| November 8, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Oyster Point Pharma, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 69242L106 (CUSIP Number) Louis S. Citron, Esq. New Enterprise Associates 1954 Greenspring Drive, Suite 600, Timonium, MD 21093 (410) 842-4000 (Name, A |
|
| November 5, 2019 |
Amended and Restated Certificate of Incorporation EX-3.1 Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF OYSTER POINT PHARMA, INC. Oyster Point Pharma, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), does hereby certify as follows: A. The name of the Corporation is Oyster Point Pharma, Inc. The original Certificate of Incorporation of the Corporation was filed with the Secre |
|
| November 5, 2019 |
Oyster Point Pharma Announces Pricing of Initial Public Offering EX-99.1 Exhibit 99.1 Oyster Point Pharma Announces Pricing of Initial Public Offering PRINCETON, N.J. – October 30, 2019 – Oyster Point Pharma, Inc., a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases, today announced the pricing of its initial public offering of 5,000,00 |
|
| November 5, 2019 |
EX-3.2 Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF OYSTER POINT PHARMA, INC. (amended and restated on October 2, 2019 and effective as of the closing of the corporation’s initial public offering) TABLE OF CONTENTS Page ARTICLE I - CORPORATE OFFICES 1 1.1 REGISTERED OFFICE 1 1.2 OTHER OFFICES 1 ARTICLE II - MEETINGS OF STOCKHOLDERS 1 2.1 PLACE OF MEETINGS 1 2.2 ANNUAL MEETING 1 2.3 SPECIAL MEETING 1 |
|
| November 5, 2019 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 30, 2019 Oyster Point Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39112 81-1030955 (State or other jurisdiction of incorporation) (Comm |
|
| November 5, 2019 |
Oyster Point Pharma Announces Closing of Initial Public Offering EX-99.2 Exhibit 99.2 Oyster Point Pharma Announces Closing of Initial Public Offering PRINCETON, N.J. November 5, 2019 Oyster Point Pharma, Inc., a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases, announced the closing of its initial public offering of 5,750,000 shar |
|
| October 31, 2019 |
OYST / Oyster Point Pharma, Inc. S-8 - - S-8 S-8 As filed with the Securities and Exchange Commission on October 31, 2019 Registration No. |
|
| October 31, 2019 |
424B4 Table of Contents Filed Pursuant to Rule 424(b)(4) Registration No. 333-234104 5,000,000 Shares COMMON STOCK This is the initial public offering of shares of common stock by Oyster Point Pharma, Inc. We are offering shares of our common stock. The initial public offering price is $16.00 per share. Prior to this offering, there has been no public market for our common stock. Our common stock |
|
| October 28, 2019 |
OYST / Oyster Point Pharma, Inc. CORRESP - - CORRESP October 28, 2019 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Healthcare & Insurance 100 F Street, N.E. Washington, D.C. 20549-3720 Attention: Sonia Bednarowski Justin Dobbie Sasha Parikh Angela Connell Re: Oyster Point Pharma, Inc. Registration Statement on Form S-1 File No. 333-234104 Acceleration Request Requested Date: Wednesday, October 3 |
|
| October 28, 2019 |
OYST / Oyster Point Pharma, Inc. CORRESP - - CORRESP October 28, 2019 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Healthcare & Insurance 100 F Street, N.E. Washington, D.C. 20549-3720 Attention: Sonia Bednarowski Justin Dobbie Sasha Parikh Angela Connell Re: Oyster Point Pharma, Inc. Registration Statement on Form S-1 File No. 333-234104 Acceleration Request Requested Date: Wednesday, October 3 |
|
| October 28, 2019 |
OYST / Oyster Point Pharma, Inc. CORRESP - - CORRESP J.P. Morgan Securities LLC 383 Madison Avenue New York, New York 10179 Cowen and Company, LLC 599 Lexington Avenue New York, New York 10022 Piper Jaffray & Co. 345 Park Avenue, Suite 1200 New York, NY 10154 October 28, 2019 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Sonia Bednarowski Justin Dobbie Sasha |
|
| October 28, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 Oyster Point Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 81-1030955 (State of incorporation or organization) (I.R.S. Employer Identification No.) 202 Carnegie Cente |
|
| October 28, 2019 |
OYST / Oyster Point Pharma, Inc. CORRESP - - CORRESP J.P. Morgan Securities LLC 383 Madison Avenue New York, New York 10179 Cowen and Company, LLC 599 Lexington Avenue New York, New York 10022 Piper Jaffray & Co. 345 Park Avenue, Suite 1200 New York, NY 10154 October 28, 2019 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Sonia Bednarowski Justin Dobbie Sasha |
|
| October 21, 2019 |
Exhibit 10.11 CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED, AND HAS BEEN MARKED WITH ?[***]? TO INDICATE WHERE OMISSIONS HAVE BEEN MADE. NON-EXCLUSIVE PATENT LICENSE AGREEMENT This Non-Exclusive Patent License Agreement (the ?Agreement?) is made as of 18th October 2019 (the ?Effective Dat |
|
| October 21, 2019 |
OYST / Oyster Point Pharma, Inc. CORRESP - - CORRESP October 21, 2019 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance Office of Healthcare & Insurance 100 F Street, N. |
|
| October 21, 2019 |
Table of Contents As filed with the Securities and Exchange Commission on October 21, 2019. |
|
| October 21, 2019 |
Form of Underwriting Agreement, including Form of Lock-up Agreement. Exhibit 1.1 OYSTER POINT PHARMA, INC. [?] Shares of Common Stock Underwriting Agreement [?], 2019 J.P. Morgan Securities LLC Cowen and Company, LLC Piper Jaffray & Co. As Representatives of the several Underwriters listed in Schedule 1 hereto c/o J.P. Morgan Securities LLC 383 Madison Avenue New York, New York 10179 c/o Cowen and Company, LLC 599 Lexington Avenue New York, New York 10022 c/o Piper |
|
| October 21, 2019 |
2019 Employee Stock Purchase Plan. Exhibit 10.4 OYSTER POINT PHARMA, INC. 2019 EMPLOYEE STOCK PURCHASE PLAN 1. Purpose. The purpose of the Plan is to provide employees of the Company and its Designated Companies with an opportunity to purchase Common Stock through accumulated Contributions. The Company intends for the Plan to have two components: a component that is intended to qualify as an ?employee stock purchase plan? under Sec |
|
| October 21, 2019 |
2019 Equity Incentive Plan and forms of agreements thereunder. Exhibit 10.3 OYSTER POINT PHARMA, INC. 2019 EQUITY INCENTIVE PLAN 1. Purposes of the Plan. The purposes of this Plan are: ? to attract and retain the best available personnel for positions of substantial responsibility, ? to provide additional incentive to Employees, Directors and Consultants, and ? to promote the success of the Company?s business. The Plan permits the grant of Incentive Stock Opt |
|
| October 21, 2019 |
Amended and Restated Certificate of Incorporation of the Registrant, as currently in effect. Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF OYSTER POINT PHARMA, INC. Oyster Point Pharma, Inc., a corporation organized and existing under the laws of the State of Delaware (the ?Corporation?), certifies that: 1. The name of the Corporation is Oyster Point Pharma, Inc. The Corporation?s original Certificate of Incorporation was filed with the Secretary of State of the State o |
|
| October 15, 2019 |
Form of Common Stock Certificate. Exhibit 4.2 ZQ|CERT#|COY|CLS|RGSTRY|ACCT#|TRANSTYPE|RUN#|TRANS# COMMON STOCK PAR VALUE $0.001 COMMON STOCK Shares OYSTER POINT PHARMA, INC. INCORPORATED UNDER THE LAWS OF THE STATE OF DELAWARE THIS CERTIFIES THAT is the owner of Certificate Number ZQ00000000 THIS CERTIFICATE IS TRANSFERABLE IN CITIES DESIGNATED BY THE TRANSFER AGENT, AVAILABLE ONLINE AT www.computershare.com SEE REVERSE FOR CERTAI |
|
| October 15, 2019 |
OYST / Oyster Point Pharma, Inc. CORRESP - - CORRESP 1301 Avenue of the Americas, 40th Floor New York, NY 10019-6022 PHONE 212. |
|
| October 15, 2019 |
As filed with the Securities and Exchange Commission on October 15, 2019. Table of Contents As filed with the Securities and Exchange Commission on October 15, 2019. |
|
| October 10, 2019 |
OYST / Oyster Point Pharma, Inc. CORRESP - - Cheap Stock Letter 1301 Avenue of the Americas, 40th Floor New York, NY 10019-6022 PHONE 212. |
|
| October 4, 2019 |
Executive Incentive Compensation Plan. Exhibit 10.10 OYSTER POINT PHARMA, INC. EXECUTIVE INCENTIVE COMPENSATION PLAN (Adopted on October 2, 2019 and effective as of the Company?s initial public offering) 1. Purposes of the Plan. The Plan is intended to increase stockholder value and the success of the Company by motivating Employees to (i) perform to the best of their abilities and (ii) achieve the Company?s objectives. 2. Definitions. |
|
| October 4, 2019 |
Amended and Restated Bylaws of the Registrant, as currently in effect. Exhibit 3.3 BYLAWS OF OYSTER POINT PHARMA, INC. Adopted on July 1, 2015 TABLE OF CONTENTS Page ARTICLE I ? MEETINGS OF STOCKHOLDERS 1 1.1 Place of Meetings 1 1.2 Annual Meeting 1 1.3 Special Meeting 1 1.4 Notice of Stockholders? Meetings 1 1.5 Quorum 2 1.6 Adjourned Meeting; Notice 2 1.7 Conduct of Business 2 1.8 Voting 2 1.9 Stockholder Action by Written Consent Without a Meeting 3 1.10 Record Da |
|
| October 4, 2019 |
Employment Offer Letter between the Registrant and Daniel Lochner. Exhibit 10.6 OYSTER POINT PHARMA, INC. July 1, 2019 Daniel Lochner [Personal address] Dear Daniel: On behalf of Oyster Point Pharma, Inc. (the ?Company?), I am pleased to offer you the position of Chief Financial Officer. The terms of this offer are as follows: 1. Employment. If you decide to join us, you will be employed on a full-time basis at the Company?s office located in Princeton, New Jerse |
|
| October 4, 2019 |
Employment Offer Letter between the Registrant and Jeffrey Nau, Ph.D., M.M.S. Exhibit 10.5 OYSTER POINT PHARMA, INC. November 1, 2017 Jeffrey Nau [Personal address] Dear Jeff: I am pleased to offer you a position with Oyster Point Pharma, Inc. (the ?Company?), as its Chief Executive Officer. If you decide to join us, you will receive an annual salary of $300,000, which will be paid semi-monthly in accordance with the Company?s normal payroll procedures. In addition, you wil |
|
| October 4, 2019 |
Outside Director Compensation Policy. Exhibit 10.9 OYSTER POINT PHARMA, INC. OUTSIDE DIRECTOR COMPENSATION POLICY (Adopted on October 3, 2019 and effective as of the Company?s initial public offering) Oyster Point Pharma, Inc. (the ?Company?) believes that the granting of equity and cash compensation to its members of the Board of Directors (the ?Board,? and members of the Board, ?Directors?) represents a powerful tool to attract, ret |
|
| October 4, 2019 |
Amended and Restated Certificate of Incorporation of the Registrant, as currently in effect. Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF OYSTER POINT PHARMA, INC. Oyster Point Pharma, Inc., a corporation organized and existing under the laws of the State of Delaware (the ?Corporation?), certifies that: 1. The name of the Corporation is Oyster Point Pharma, Inc. The Corporation?s original Certificate of Incorporation was filed with the Secretary of State of the State o |
|
| October 4, 2019 |
Power of Attorney (see page II-6 to this Form S-1). Table of Contents As filed with the Securities and Exchange Commission on October 4, 2019. |
|
| October 4, 2019 |
Exhibit 10.1 OYSTER POINT PHARMA, INC. INDEMNIFICATION AGREEMENT This Indemnification Agreement (this ?Agreement?) is dated as of , 2019 and is between Oyster Point Pharma, Inc., a Delaware corporation (the ?Company?), and [insert name of indemnitee] (?Indemnitee?). RECITALS WHEREAS, indemnitee?s service to the Company substantially benefits the Company. WHEREAS, individuals are reluctant to serve |
|
| October 4, 2019 |
OYST / Oyster Point Pharma, Inc. CORRESP - - CORRESP 1301 Avenue of the Americas, 40th Floor New York, NY 10019-6022 PHONE 212. |
|
| October 4, 2019 |
2016 Equity Incentive Plan, as amended, and forms of agreement thereunder. Exhibit 10.2 OYSTER POINT PHARMA, INC. 2016 EQUITY INCENTIVE PLAN (as of February 13, 2019) 1. Purposes of the Plan. The purposes of this Plan are: ? to attract and retain the best available personnel for positions of substantial responsibility, ? to provide additional incentive to Employees, Directors and Consultants, and ? to promote the success of the Company?s business. The Plan permits the gr |
|
| October 4, 2019 |
Exhibit 4.1 OYSTER POINT PHARMA, INC. AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT February 15, 2019 TABLE OF CONTENTS Page Section 1 Definitions 1 1.1 Certain Definitions 1 Section 2 Registration Rights 3 2.1 Requested Registration 3 2.2 Company Registration 5 2.3 Registration on Form S-3 6 2.4 Expenses of Registration 7 2.5 Registration Procedures 7 2.6 Indemnification 8 2.7 Information by Hol |
|
| October 4, 2019 |
Form of Change in Control and Severance Agreement. Exhibit 10.8 OYSTER POINT PHARMA, INC. CHANGE IN CONTROL AND SEVERANCE AGREEMENT This Change in Control and Severance Agreement (the ?Agreement?) is made between Oyster Point Pharma, Inc. (the ?Company?) and (the ?Executive?), effective as of , 2019 (the ?Effective Date?). This Agreement provides certain protections to the Executive in connection with a change in control of the Company or in conne |
|
| October 4, 2019 |
Employment Offer Letter between the Registrant and John Snisarenko. Exhibit 10.7 OYSTER POINT PHARMA, INC. John Snisarenko August 2, 2019 [Personal Home Address] Dear John: On behalf of Oyster Point Pharma, Inc. (the ?Company?), I am pleased to offer you the position of Chief Commercial Officer. The terms of this offer are as follows: 1. Employment. If you decide to join us, you will be employed on a full-time basis, and your first day of employment will be Septem |
|
| October 4, 2019 |
Exhibit 3.2 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF OYSTER POINT PHARMA, INC. Oyster Point Pharma, Inc., a corporation organized and existing under the laws of the State of Delaware (the ?Corporation?), does hereby certify as follows: A. The name of the Corporation is Oyster Point Pharma, Inc. The original Certificate of Incorporation of the Corporation was filed with the Secretary of |
|
| October 4, 2019 |
Consent of Aimee Weisner to be named as director. Exhibit 99.1 CONSENT TO BE NAMED I hereby confirm my consent to be named as a director of Oyster Point Pharma, Inc. (the ?Company?), in the Registration Statement on Form S-1 filed by the Company with the Securities and Exchange Commission, including any and all amendments and post-effective amendments thereto and any amendments filed under Rule 462(b) (collectively, the ?Registration Statement?). |
|
| October 4, 2019 |
Exhibit 3.4 AMENDED AND RESTATED BYLAWS OF OYSTER POINT PHARMA, INC. (amended and restated on October 2, 2019 and effective as of the closing of the corporation?s initial public offering) TABLE OF CONTENTS Page ARTICLE I - CORPORATE OFFICES 1 1.1 REGISTERED OFFICE 1 1.2 OTHER OFFICES 1 ARTICLE II - MEETINGS OF STOCKHOLDERS 1 2.1 PLACE OF MEETINGS 1 2.2 ANNUAL MEETING 1 2.3 SPECIAL MEETING 1 2.4 AD |
|
| September 6, 2019 |
Table of Contents As confidentially submitted to the Securities and Exchange Commission on September 6, 2019. |
|
| September 6, 2019 |
OYST / Oyster Point Pharma, Inc. DRSLTR - - DRSLTR 1301 Avenue of the Americas, 40th Floor New York, NY 10019-6022 PHONE 212.999.5800 FAX 212.999.5899 www.wsgr.com September 6, 2019 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance Office of Healthcare & Insurance 100 F Street, N.E. Washington, D.C. 20549-3720 Attention: Sonia Bednarowski Justin Dobbie Sasha Parikh Angela Connell Re: Oyster Point Pharma, Inc. Draf |
|
| July 25, 2019 |
DRS 1 filename1.htm Table of Contents As confidentially submitted to the Securities and Exchange Commission on July 24, 2019. This draft registration statement has not been publicly filed with the Securities and Exchange Commission and all information herein remains strictly confidential. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTR |
